Baricitinib on Hold in the U.S. for RA, for Now
The FDA has nixed Eli Lilly's and Inctye's application for baricitinib in its current form asking for additional safety and clinical data.
Rituximab for PV Granted Breakthrough Therapy Designation
Designated a breakthrough therapy for pemphigus vulgaris, rituximab has been shown to work better than prednisone alone and with fewer adverse events, researchers report in The Lancet.
Adalimumab-atto: It’s Indications and Key Takeaways
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
Newly Approved Treatment for Psoriasis in Ixekizuma
Ixekizumab, one of three anti-IL-17 agents for moderate-to-severe plaque psoriasis, has been approved by the FDA for plaque psoriasis — a disease that goes untreated for most patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.